Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology
Head and Neck Cancer
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Cetuximab at Either 500 or 750mg/m2 Every Other Week for Platinum Refractory Cancer of the Head and Neck
RTOG 0522: A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
RTOG 0615: A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
A Study of TNFerade ™ with Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients with Head and Neck Cancer
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients with Head and Neck Cancer
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Cancer: Adults with Head and Neck Cancer Wanted for a Research Study
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
People with Head and Neck Squamous Cell Carcinoma are asked to participate in a research study being conducted by Long Island Jewish Medical Center.
A Phase III, Multicenter, Randomized,Double-Blind,Placebo-Controlled Study to Assess Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Head And Neck
Men and Women 18 years and older wanted for head and neck cancer study.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
If the patient has incurable Head & Neck cancer and has failed at least one course of standard platinum based chemotherapy, he/she may be eligible for this clinical trial.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.
